Abstract Search

ea0090p6 | Adrenal and Cardiovascular Endocrinology | ECE2023

Patients with NF1 need routine hormonal screening towards pheochromocytoma

Rzepka Ewelina , Bogusławska Anna , Kurzyńska Anna , Opalinska Marta , Przybylik-Mazurek Elwira , Hubalewska-Dydejczyk Alicja , Gilis-Januszewska Aleksandra

Up to 40% of pheochromocytoma cases have a genetic background. The prevalence of pheochromocytoma in neurofibromatosis type 1 (NF1) was reported to be from 0.1 to 5.7%. However, the actual incidence of pheochromocytoma in NF1 seems to be underestimated. Current recommendations on NF1 do not include systematic biochemical screening for the presence of pheochromocytoma. Our aim was to analyse clinicopathological characteristics of pheochromocytoma in the course of NF1 syndrome w...

2 shares

ea0073aep509 | Pituitary and Neuroendocrinology | ECE2021

Self-administration of long-acting somatostatin analogues in NET patients forced by the COVID-19 pandemic – does it affect the clinical outcome?

Opalinska Marta , Anna Kurzynska , Staszczak Anna Sowa , Joanna Palen-Tytko , Zwinczewska Helena , Karolina Morawiec-Slawek , Hubalewska-Dydejczyk Alicja

BackgroundSomatostatin analogues (SSA) (octreotide and lanreotide) are recommended as a first line treatment of locally advanced or metastatic well-differentiated neuroendocrine tumors (NETs) with a good expression of somatostatin receptor (SSTR). Both of them are usually used in injection repeated every 4 weeks.The study objectiveWas to compare the way of SSA administration (injection performed by profession...

0 shares

Endocrine Abstracts

Patients with NF1 need routine hormonal screening towards pheochromocytoma

Self-administration of long-acting somatostatin analogues in NET patients forced by the COVID-19 pandemic – does it affect the clinical outcome?

BiosciAbstracts